medigraphic.com
ISSN 2007-6800 (Impreso)

2020, Número S2

<< Anterior Siguiente >>

Rev Mex Traspl 2020; 9 (S2)


Enfermedad hepática y trasplante durante la pandemia COVID-19/SARS-CoV-2

Leal-Leyte P, Zamora-Valdés D, Méndez-Sánchez N

Idioma: Español
Referencias bibliográficas: 78
Paginas: 206-215
Archivo PDF: 278.65 Kb.


RESUMEN

Introducción: La pandemia por SARS-CoV-2/COVID-19 ha afectado todas las áreas de la atención médica, particularmente la atención de enfermedades crónicas. La enfermedad hepática crónica es altamente prevalente en nuestro país y representa una de las principales causas de mortalidad general. Objetivo: En esta revisión, analizamos la literatura disponible hasta el 5 de junio de 2020 sobre el impacto de SARS-CoV-2/COVID-19 en enfermedades hepáticas y en la actividad de trasplante hepático. Material y métodos: Realizamos una búsqueda en PubMed con los términos «liver» (hígado), «hepatic» (hepático), o «transplant» (trasplante) y «COVID-19» o «SARS-CoV-2» contenidos en el título o el resumen de la categoría «Journal Articles» durante el último año. Los artículos fueron analizados por dos revisores de forma independiente. Resultados: Encontramos 276 resultados, de los cuales 54 artículos cumplieron con los criterios de inclusión. La mayor parte de la información disponible proviene de recomendaciones de expertos o consensos. Los organismos reguladores de donación y trasplante han desarrollado algoritmos específicos para su región con el objetivo de guiar la actividad de trasplantes durante la pandemia. Los programas, en general, han reportado disminución en sus actividades. Los resultados de infección por SARS-CoV-2 en receptores de trasplante hepático no son concluyentes y la evaluación del donante para la infección es ampliamente recomendada. Conclusión: La pandemia por SARS-CoV-2/COVID-19 ha modificado las prácticas de todos los programas de trasplante alrededor del mundo. La comunidad de trasplantes se encuentra frente a un escenario difícil con evidencia científica escasa que guíe la toma de decisiones sobre el futuro y la atención óptima de pacientes con enfermedad hepática terminal en necesidad de trasplante, durante y después de la pandemia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yan R, Zhang Y, Li Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367: 1444-1448.

  2. Chai X, Hu L, Zhang Y et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020; 2020.02.03.931766.

  3. Zhao B, Ni C, Gao R et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020; 1-5.

  4. Parohan M, Yaghoubi S, Seraj A. Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies. Hepatol Res. 2020.

  5. Kukla M, Skonieczna-Żydecka K, Kotfis K et al. COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature. J Clin Med. 2020; 9 (5): E1420.

  6. Mao R, Qiu Y, He JS et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020.

  7. Wang H, Qiu P, Liu J, Wang F, Zhao Q. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020.

  8. Youssef M, Hussein M, Attia AS et al. COVID-19 and Liver Dysfunction: a systematic review and meta-analysis of retrospective studies. J Med Virol. 2020.

  9. Kunutsor SK, Laukkanen JA. Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis. J Infect. 2020.

  10. Sultan S, Altayar O, Siddique SM et al. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020.

  11. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091.

  12. Dufour DR, Lott JA, Nolte FS et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000; 46: 2050-2068.

  13. Koch DG, Speiser JL, Durkalski V et al. The natural history of severe acute liver injury. Am J Gastroenterol. 2017; 112: 1389-1396.

  14. Zou Y, Guo H, Zhang Y et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends. 2020.

  15. Philips CA, Ahamed R, Augustine P. SARS-CoV-2 related liver impairment - perception may not be the reality. J Hepatol. 2020.

  16. Qi X, Wang J, Li X et al. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int. 2020.

  17. Qi X, Liu Y, Wang J et al. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 2020.

  18. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis. 2020; 5.

  19. Moon AM, Webb GJ, Aloman C et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020.

  20. Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in united states: a multi-center research network study. Gastroenterology. 2020.

  21. Wang X, Fang X, Cai Z et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. Research (Wash D C). 2020; 2020: 2402961.

  22. Da BL, Im GY, Schiano TD. COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology 2020.

  23. Reddy KR. SARS-CoV-2 and the liver: considerations in hepatitis B and hepatitis C infections. Clin Liver Dis (Hoboken). 2020; 15: 191-194.

  24. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020; 26: 2323-2332.

  25. Schaller T, Hirschbuhl K, Burkhardt K et al. Postmortem examination of patients with COVID-19. JAMA. 2020.

  26. Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF et al. Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology. 2020.

  27. Wang W, Xu Y, Gao R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020.

  28. Zhang W, Du RH, Li B et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020; 9: 386-389.

  29. Du M, Cai G, Chen F et al. Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID-19. Gastroenterology. 2020; 158: 2298-2301.

  30. Xiao F, Tang M, Zheng X et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158: 1831-1833.

  31. Castro Filho EC, Castro R, Fernandes FF, Pereira G, Perazzo H. Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies. Gastrointest Endosc. 2020.

  32. Repici A, Pace F, Gabbiadini R et al. Endoscopy units and the COVID-19 outbreak: a multi-center experience from Italy. Gastroenterology. 2020.

  33. Abbate M, Rottoli D, Gianatti A. COVID-19 Attacks the Kidney: ultrastructural evidence for the presence of virus in the glomerular epithelium. Nephron. 2020; 1-2.

  34. Roufosse C, Curtis E, Moran L et al. Electron microscopic investigations in COVID-19: not all crowns are coronas. Kidney Int. 2020.

  35. Fang FC, Naccache SN, Greninger AL. The laboratory diagnosis of COVID-19-- frequently-asked questions. Clin Infect Dis. 2020.

  36. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. Clin Infect Dis. 2020.

  37. Ai T, Yang Z, Hou H et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020; 200642.

  38. Theel ES, Slev P, Wheeler S et al. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol. 2020.

  39. Huang AT, Garcia-Carreras B, Hitchings MDT et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv. 2020; 2020.04.14.20065771.

  40. Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003; 3: 977-981.

  41. Kumar D, Manuel O, Natori Y et al. COVID-19: A global transplant perspective on successfully navigating a pandemic. Am J Transplant. 2020.

  42. Dominguez-Gil B, Coll E, Fernandez-Ruiz M et al. COVID-19 in Spain: transplantation in the midst of the pandemic. Am J Transplant. 2020.

  43. Agnes S, Andorno E, Avolio AW et al. Preliminary analysis of the impact of COVID-19 outbreak on italian liver transplant programs. Liver Transpl. 2020.

  44. Massoumi H, Rocca J, Frager S, Kinkhabwala M. COVID-19 infection in early post-operative period after liver transplantation. Liver Transpl. 2020.

  45. Agopian V, Verna E, Goldberg D. Changes in liver transplant center practice in response to COVID-19: unmasking dramatic center-level variability. Liver Transpl. 2020.

  46. Boyarsky BJ, Po-Yu Chiang T, Werbel WA et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020.

  47. Saigal S, Gupta S, Sudhindran S et al. Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI). Hepatol Int. 2020.

  48. Verma S, Aleen Agarwal S, Chikkala BR et al. Living donor liver transplants for sick recipients during COVID-19 pandemic- An experience from a tertiary center in India. Am J Transplant. 2020.

  49. Hong HL, Kim SH, Choi DL, Kwon HH. A case of coronavirus disease 2019-infected liver transplant donor. Am J Transplant. 2020.

  50. Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three months in England. BMJ. 2020; 368: m1106.

  51. Aminian A, Safari S, Razeghian-Jahromi A, Ghorbani M, Delaney CP. COVID-19 Outbreak and surgical practice: unexpected fatality in perioperative period. Ann Surg. 2020.

  52. Lei S, Jiang F, Su W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020; 100331.

  53. Chew CA, Iyer SG, Chieh Kow AW et al. An international multicentre study of protocols for liver transplantation during a pandemic: a case for quadripartite equipoise. J Hepatol. 2020.

  54. Moeckli B, Peloso A, Oldani G et al. The swiss approach to the COVID-19 outbreak. Am J Transplant. 2020.

  55. Muller X, Tilmans G, Chenevas-Paule Q et al. Strategies for liver transplantation during the SARS CoV-2 outbreak preliminary experience from a single center in France. Am J Transplant. 2020.

  56. Angelico R, Trapani S, Manzia TM et al. The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs. Am J Transplant. 2020.

  57. Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382: 1663-1665.

  58. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145.

  59. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020; 26: 832-834.

  60. Qin J, Wang H, Qin X et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020.

  61. Liu B, Wang Y, Zhao Y et al. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. Am J Transplant. 2020.

  62. Bollipo S, Kapuria D, Rabiee A et al. One world, one pandemic, many guidelines: management of liver diseases during COVID-19. Gut. 2020.

  63. Lau G, Ward JW. Synthesis of liver associations recommendations for hepatology and liver transplant care during the COVID-19 pandemic. Clin Liver Dis (Hoboken). 2020; 15: 204-209.

  64. Perazzo H, Piedade J, Castro R et al. COVID-19: an overview of worldwide recommendations for management of patients with liver diseases or liver transplantation. Clin Gastroenterol Hepatol. 2020.

  65. Xia T, Wang Y. Coronavirus disease 2019 and transplantation: the combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome. Am J Transplant. 2020.

  66. Morand A, Roquelaure B, Colson P et al. Child with liver transplant recovers from COVID-19 infection. A case report. Arch Pediatr. 2020.

  67. Hammami MB, Garibaldi B, Shah P et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. Am J Transplant. 2020.

  68. Zhong Z, Zhang Q, Xia H et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. 2020.

  69. Tschopp J, L’Huillier AG, Mombelli M et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the swiss transplant cohort study. Am J Transplant. 2020.

  70. Gao F, Zheng KI, Gu JY, George J, Zheng MH. COVID-19 and liver transplantation: Lessons learned from three reported cases. Transpl Infect Dis. 2020; e13335.

  71. Lee BT, Perumalswami PV, Im GY, Florman S, Schiano TD. COVID-19 in liver transplant recipients: an initial experience from the U.S. epicenter. Gastroenterology. 2020.

  72. Hoek RAS, Manintveld OC, Betjes MGH et al. Covid-19 in solid organ transplant recipients: a single center experience. Transpl Int. 2020.

  73. Fung M, Chiu CY, DeVoe C et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: a case series from the united states. Am J Transplant. 2020.

  74. Muller H, Kniepeiss D, Stauber R et al. Recovery from COVID-19 following hepatitis C, human immunodeficiency virus infection and liver transplantation. Am J Transplant. 2020.

  75. Yi SG, Rogers AW, Saharia A et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation. 2020.

  76. Modi AR, Koval CE, Taege AJ et al. Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. Transpl Infect Dis. 2020; e13351.

  77. Patrono D, Lupo F, Canta F et al. Outcome of COVID-19 in liver transplant recipients: a preliminary report from northwestern Italy. Transpl Infect Dis. 2020; e13353.

  78. Belli LS, Duvoux C, Karam V et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol. 2020.




2020     |     www.medigraphic.com